Figure EV5. Atorvastatin pre‐treatment ameliorated renal I/R injury by reducing lipid accumulation via Ces1 and enhancing fatty acid oxidation.

• A
  Experimental design for atorvastatin prevention treatment on renal I/R injury.
• B
  Serum TG (triglyceride) and TC (cholesterol) levels of indicated groups.
• C
  Representative H&E staining and pathological scores of I/R‐injured kidneys from mice pre‐treated with vehicle or atorvastatin (pre‐ATO, 20 mg/kg, i.g.). Scale bar = 100 μm.
• D
  mRNA levels of Kim1 and Ngal of vehicle and pre‐ATO.
• E, F
  Representative Oil Red O staining with quantitative results (E, scale bar = 100 μm), renal TG (triglyceride) and TC (cholesterol) levels (F) of indicated groups.
• G
  mRNA levels of fatty acid oxidation related genes of indicated groups.
• H–J
  mRNA levels of Ces1 (H), representative immunoblots with quantitative results of G9a and Ces1 (I), and carboxylesterase enzymatic activity (J) of indicated groups.
• K, L
  Representative immunostaining for CD3, Ly6G, and F4/80 (K) and quantitative results (L) of indicated groups. Scale bar = 50 μm.
• M
  Representative immunoblots with quantitative results of p‐Rip3 and p‐Mlkl of indicated groups.

Data information: Six mice per group. In (B–J, L and M), data were presented as means ± SD. Panels C–E, F (TG), G (except Acadm), H–J, L and M were analyzed with 2‐tailed, unpaired Student's t test. Panels B, F (TC) and G (Acadm) were analyzed by Mann–Whitney U test. *P < 0.05; **P < 0.01.

Source data are available online for this figure.